



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drug Classes on
August 3, 2017**

Antidiabetics, Non-Insulin, GLP-1 Receptor Agonists

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Adlyxin (Subcutaneous) Pen* and *Soliqua (Subcutaneous) Pen* with no additional changes in the class and the intention to discuss this class for changes at a future meeting.

Bronchodilators, Anticholinergics

The DUR Board recommended *Preferred* status for *Bevespi Aerosphere (Inhalation) Aerosol* with no additional changes in this class.

Duchenne Muscular Dystrophy Steroids

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Emflaza (Oral) Tablet*. The DUR Board further recommended reviewing each *Emflaza* request on a case-by-case basis.

Dermatologic, Atopic Dermatitis

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Eucriisa (Topical) Ointment* contingent upon the Department of Community Health reviewing the recent supplemental rebate offer.

Vitamin D Analogs

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Rayaldee (Oral) Capsule*.